Pharmaceutical Profiles and Pharmacia Corporation Announce First Ever Multiple Study Agreement for Programme of Human Drug Absorption Studies

Apr 25, 2001, 01:00 ET from Pharmaceutical Profiles

    NOTTINGHAM, England, April 25 /PRNewswire/ -- Pharmaceutical Profiles, an
 early phase development company focused on improving the decision-making
 process in early drug or product development, is to initiate a programme of
 human drug absorption studies for Pharmacia Corporation.
     Pharmaceutical Profiles will be implementing key pharmacoscintigraphic
 investigations for medications currently being developed by the pharmaceutical
 company.
     Pharmacia is the latest of a growing list by pharmaceutical and biotech
 companies using human absorption studies designed to establish a 'route-map'
 for drug development.  This process has the potential to save significant
 financial and time resources by improving decision-making in early
 development.
     The process utilised by Pharmaceutical Profiles involves the use of
 scintigraphic imaging and Enterion capsule technology provided by Phaeton
 Research.  This intelligent capsule technology delivers new drugs, new
 formulations or new drug delivery technologies in a range of physical forms --
 such as a solution or a powder -- to specific regions of the human
 gastrointestinal tract, such as the proximal small bowel, the distal small
 bowel and the ascending colon.  The findings of the study provide a
 'route-map' for subsequent drug development.
     Pharmaceutical Profiles' Chief Executive Officer, Dr Ian Wilding, believes
 this will be highly advantageous for Pharmacia, commenting:  "This
 sophisticated imaging technique accurately tracks the capsules' location in
 the gut, enabling it to release the drug at the required site in the
 intestine; blood sampling can then be commenced to establish the PK profile of
 the drug.  This approach will establish the opportunity to develop
 'once-a-day' formulations and thereby accelerate the drug development process
 by facilitating informed decision-making."
 
      Visit the Pharmaceutical Profiles web site at:
      http://www.pharmprofiles.co.uk/
 
 

SOURCE Pharmaceutical Profiles
    NOTTINGHAM, England, April 25 /PRNewswire/ -- Pharmaceutical Profiles, an
 early phase development company focused on improving the decision-making
 process in early drug or product development, is to initiate a programme of
 human drug absorption studies for Pharmacia Corporation.
     Pharmaceutical Profiles will be implementing key pharmacoscintigraphic
 investigations for medications currently being developed by the pharmaceutical
 company.
     Pharmacia is the latest of a growing list by pharmaceutical and biotech
 companies using human absorption studies designed to establish a 'route-map'
 for drug development.  This process has the potential to save significant
 financial and time resources by improving decision-making in early
 development.
     The process utilised by Pharmaceutical Profiles involves the use of
 scintigraphic imaging and Enterion capsule technology provided by Phaeton
 Research.  This intelligent capsule technology delivers new drugs, new
 formulations or new drug delivery technologies in a range of physical forms --
 such as a solution or a powder -- to specific regions of the human
 gastrointestinal tract, such as the proximal small bowel, the distal small
 bowel and the ascending colon.  The findings of the study provide a
 'route-map' for subsequent drug development.
     Pharmaceutical Profiles' Chief Executive Officer, Dr Ian Wilding, believes
 this will be highly advantageous for Pharmacia, commenting:  "This
 sophisticated imaging technique accurately tracks the capsules' location in
 the gut, enabling it to release the drug at the required site in the
 intestine; blood sampling can then be commenced to establish the PK profile of
 the drug.  This approach will establish the opportunity to develop
 'once-a-day' formulations and thereby accelerate the drug development process
 by facilitating informed decision-making."
 
      Visit the Pharmaceutical Profiles web site at:
      http://www.pharmprofiles.co.uk/
 
 SOURCE  Pharmaceutical Profiles